Finally, we'd note we see both Phison and SIMO as significant beneficiaries of such a shift, given the need to manage NAND storage, and China's less competitive positioning in the NAND controller space (and likely some reluctance from Western brands to use Chinese built controllers, even for SKUs a
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersenThe high-dose regimen of nusinersen also slowed neurodegeneration more rapidly, as measured by neurofilament, than the 12 mg regimen CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) today announced that published results from the Phase 2/3 DEVOTE study ...
While TSMC has exited the GaN space both VIS and GF have licensed TSMC's 650 and 80V technology. We tend to see GF as more likely to realize greater benefits if GaN demand indeed grows at an accelerated pace, given GF's pre-existing efforts in the space, which TSMC's IP only builds upon. We'd also
We would also point out that to date, China has invested over $15B in its domestic quantum ecosystem, compared to just under $8B in the US (per QED-C State of Global Quantum Industry), once again highlighting the need for additional Federal funding of the US' quantum ecosystem.Given the vested inte
Figure 1. 4Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusNote: 4Q revenue guide in the range of $56-$59B.Meta delivered strong 4Q results. Revenue in the quarter reached $59.9B (+23.8% Y/Y), ahead of consensus of $58.4B (+20.8% Y/Y) by ~3%. Revenue was well above the high
In this first take following tonight’s results, we focus on: 1. Jaw-dropping revenue acceleration trumps heavy investment, easily 2. Ad growth powered by impressions, with solid pricing too 3. 2026 expense guide well above consensus but operating income still growing 4. A wide range for 2026 capex guidance but still above Street
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.